Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Olysio

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Olysio was produced by Janssen.

Remicade safe from biosimilar competition this year, says J&J

Remicade safe from biosimilar competition this year, says J&J

On the downside, hepatitis C therapy Olysio/Sovriad (simeprevir) continued its decline in the face of strong competition in the marketplace from Gilead and AbbVie, falling 86% to just $32m in

2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky

2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.

J&J's share buyback 'doesn't prevent acquisitions'

J&J's share buyback 'doesn't prevent acquisitions' disease and arthritis drug Remicade (infliximab) and Olysio (simeprevir) for hepatitis C virus offset by growth in newer products. ... Olysio continued its slide in the face of competition from new HCV drugs from Gilead and AbbVie, with sales dropping

Taking a strategic approach

Taking a strategic approach Meanwhile, for Olysio (simeprevir) - one of several new oral drugs that mark a major step forward in hepatitis C treatment - it was an innovative 'pay-if-you-clear' scheme that persuaded

First-ever World Hepatitis Summit calls for national programmes

First-ever World Hepatitis Summit calls for national programmes Drugs such as AbbVie's Exviera (dasabuvir), Johnson &Johnson's Olysio (simprevir), Gilead's Sovaldi (sofosbuvir) and Bristol-Myers Squibb's Daklinza (daclatasvir) have essentially revolutionised treatment, but the latter two

1 2 3 4 5 6 7 8 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...